Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 55
The GLP-1 segment accounts for 11% of the total diabetes
care market in the US
US GLP-1 market
GLP-1 value
in bDKK
VictozaⓇ
dulaglutide
albiglutide Share of total
exenatide
diabetes care
market
Key observations for VictozaⓇ in the US market
• VictozaⓇ volume market share within the GLP-1 segment
is 51%¹
35
12%
30
CAGR value¹: 40.9%
10%
25
8%
20
Around 85% of commercial and around 90% of Medicare
Part D lives are covered without restrictions²
• Around 65% of new patients are new to treatment or
from OAD-only regimens³
6%
15
•
4%
Close to 70% of prescriptions are for the 3-pen pack¹
10
2%
0
Aug
2011
0%
Aug
2016
1 CAGR for 5-year period
Source: IMS Monthly MAT August, 2016 value figures (DKK)
changing
diabetes®
1 IMS monthly NPA data, August 2016
2 Fingertip Formulary, July 2016; unrestricted includes covered or better access
3 IMS LRX Weekly, WE 09/09/2016
novo nordiskView entire presentation